Diseases

Arterys Inc declared its fifth 510 (k) clearance for Arterys Oncology AI suite and is milestone indicative of the company's momentum in applying AI to further medical imaging accuracy…
Read More...

Applied artificial intelligence healthcare company, Viz.ai asserted that the US FDA has extended a De Novo request for the first-ever Computer -Aided Triage and Notification Platform to…
Read More...

DreaMed Diabetes asserted that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes. DreaMed…
Read More...

Evofem Biosciences aiming to meet women's unmet healthcare needs asserted completion of enrollment in its Phase 3 Clinical Trial evaluating Amphora vaginal gel for the prevention of…
Read More...

Citius Pharmaceuticals emphasizing on adjunctive cancer care and critical care drug products affirmed the enrollment of first patient into the Mino-Lok Phase 3 Clinical Trial for…
Read More...

Eisai declared positive results of Phase 3 study for its discovered and developed anticancer agent lenvatinib mesylate in patients grappling with unresectable hepatocellular carcinoma…
Read More...

Merck KGaA, Darmstadt, Germany, and Pfizer assert results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or…
Read More...

Tusker Medical announced the enrollment of first- in-office patients in the OTTER Study implied for Tusker's  TULA (Tubes Under Local Anesthesia) System. Via an approved Investigational…
Read More...

ImmunoQure will collaborate with Servier to advance ImmunoQure's therapeutic human Interferon-α autoantibody through preclinical development and into the clinic where Servier will be…
Read More...

Spineology is exhilarated to declare that enrollment stands complete in the SCOUT clinical trial. The SCOUT (Spineology Clinical Outcomes Trial) IDE, conducted under an FDA-approved…
Read More...

Glooko declared that the US FDA has conceded its Mobile Insulin Dosing System (MIDS) for the titration of long-acting insulin for people with type 2 diabetes. The system includes…
Read More...

IRX Therapeutics asserted that Phase 2 double-blind, randomized, placebo-controlled clinical trial of IRX-2 in women has commenced with squamous cervical intraepithelial neoplasia 3…
Read More...

Neurocrine Biosciences announced that the US FDA has provided assistance on the regulatory path forward to support the New Drug Application for opicapone, an investigational drug for…
Read More...

Novartis division, Sandoz asserted that the US FDA ha sanctioned the roll out and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa was developed under a…
Read More...

Roche asserted that it has received FDA clearance for the cobas Factor II and Factor V Test for use on the cobas 4800 system. The test enables laboratories to simultaneously evaluate …
Read More...

FDA has approved a certain Erleada for the treatment of patient inflicted with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of…
Read More...

Mallinckrodt plc  confirmed the enrollment of first patient for the company's Phase 1 study evaluating the safety and tolerance of ExpressGraft C9T1 skin tissue in the treatment of…
Read More...

Division of Valeant Pharmaceuticals International, Inc., Ortho Dermatologics asserted that the U.S Food and Drug Administration accepted the New Drug Application for JEMDEL  …
Read More...

Amgen asserted that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration will assess the data supporting the BLINCYTO supplemental Biologics License…
Read More...